Buying PT-141 in the USA: the Lactam Bridge and Receptor Selectivity

PT-141 is a cyclic heptapeptide and the most receptor-selective member of the melanocortin group commonly held in research inventories. It is also the one most often misfiled, because it sits structurally next to melanotan-II and behaves quite differently at the receptor.

Structural lineage

The melanocortin peptides descend from α-MSH, a linear thirteen-residue sequence. Melanotan-II is a cyclic analog of it, closed through a lactam bridge. PT-141 is derived from melanotan-II by removing the C-terminal amide and leaving a free carboxylic acid in its place.

That single edit is the whole story: small by mass, large by pharmacology, and the reason the two cannot be treated as variants of one another in an experimental design. PT-141 also appears in the literature under its international non-proprietary name, bremelanotide.

Selectivity is the point

There are five melanocortin receptor subtypes. MC1R is the pigmentation-associated one; MC3R and MC4R are the centrally expressed pair; MC2R responds to ACTH rather than to α-MSH analogs; MC5R is the least characterized of the set.

Melanotan-II is a broad agonist across MC1R, MC3R, MC4R and MC5R. PT-141 keeps activity at MC3R and MC4R while showing markedly reduced potency at MC1R. For anyone using these as receptor tools that is the entire case for holding both: comparing them isolates the MC1R-dependent component of whatever is being measured, which neither compound can do alone.

Our overview of melanocortin receptor subtypes and selectivity sets the family out in more detail. The indexed literature is at PubMed.

Picking the readout from the coupling

Melanocortin receptors are class A GPCRs coupled to Gαs. Activation drives adenylate cyclase and raises intracellular cAMP, so a cAMP accumulation assay is the correct default.

Worth stating plainly, because the wrong instrument returns a confident null. A calcium flux assay — right for a Gαq-coupled receptor such as KISS1R, see kisspeptin-10 and KISS1R signaling — will read a genuinely active melanocortin agonist as inactive. Choosing the assay from the receptor’s coupling rather than from habit eliminates a whole class of wasted work.

Subtype selectivity has to be designed for as well, not assumed. A line expressing several melanocortin receptors reports a composite, and a selectivity claim needs each subtype measured separately in a line expressing one.

The lactam bridge, analytically

PT-141 is cyclized through a lactam rather than a disulfide, and the distinction carries further than it first appears.

A disulfide is reversible: reducing agents open it, and thiol-disulfide exchange proceeds whenever a free thiol is around. A lactam is an amide bond, unaffected by dithiothreitol or β-mercaptoethanol, so PT-141 is unusually robust to buffer components that would compromise a disulfide-bridged peptide. The general case is in cyclic versus linear peptides.

For identity checking the consequence runs the other way. With no reduced form to look for, the informative comparison is against the cyclic sequence itself, and the impurity to watch is the uncyclized linear precursor — heavier than the intended product by one water molecule, about 18 daltons. That is a wider gap than the one-dalton amide-versus-acid difference elsewhere in peptide chemistry, so it resolves cleanly, but only if the certificate reports both calculated and observed mass. Our guides to reading a certificate of analysis and how purity and identity are verified cover what each method can resolve.

Telling it from melanotan-II on paper

Since the two differ by the loss of an amide group they are close in mass and close on a reversed-phase column. A retention time that matches expectation is therefore weak evidence of which one is in the vial, particularly in a laboratory holding both.

Mass discriminates them, and the sequence printed on the certificate deserves reading rather than skimming. Where both are in inventory, label aliquots with compound and batch at the moment of reconstitution rather than afterwards — see inventory, labels and records. Confusing two melanocortin agonists with different subtype profiles produces results that look like biology and are not.

Handling

PT-141 ships as lyophilized powder and is stable sealed, cold and dry. Let the vial reach room temperature before opening: a cold vial opened into a warm room pulls moisture onto the cake, and water drives hydrolysis and deamidation in storage. See storage and stability.

Cyclic peptides of this size go into aqueous buffer readily, so the usual solubility troubles are milder here than with longer or more hydrophobic sequences. What remains are the ordinary risks: adsorption losses at low working concentrations, which flatten the bottom of a dose-response curve, and freeze-thaw cycling of a reconstituted stock. Aliquot once into single-use volumes — see aliquoting reconstituted peptides.

The milligram figure on the vial is gross weight. Counter-ion and residual water are part of that mass and not part of the peptide, so molarity calculated from the label is overstated. See net peptide content explained.

Products

PT-141 10mg, listed alongside melanotan-II and melanotan-I under melanocortin peptides. Batch certificates are published on the certificates page.

ExoLabz supplies compounds for laboratory research use only. Nothing on this page is medical advice or a suggestion of human or veterinary use. These compounds hold no FDA approval for human use.